Norroy Bioscience Co., Ltd
Clinical trials sponsored by Norroy Bioscience Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a single injection reveal hidden kidney cancer? Results expected Mar 2027 (estimated)
- New scan could spot hidden prostate cancer spread Results expected Jun 2027 (estimated)
-
New scan could spot returning prostate cancer earlier
Diagnosis Recruiting nowThis study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…
Phase 3 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
New scan could spot hidden prostate cancer spread
Diagnosis Recruiting nowThis phase 3 trial is testing a new radioactive imaging agent called 68Ga-NYM032, given as an injection before a PET/CT scan, in 365 men newly diagnosed with prostate cancer. The goal is to see if this scan can accurately detect whether the cancer has spread to pelvic lymph nodes…
Phase 3 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC